Quantitation of circulating immune complexes in human serum by the Raji cell and F(ab')2 anti-C3 micro enzyme immunoassays.

Important note: Information in this article was accurate in 1986. The state of the art may have changed since the publication date.

Quantitation of circulating immune complexes in human serum by the Raji cell and F(ab')2 anti-C3 micro enzyme immunoassays.

J Immunol Methods. 1985 Nov 7;83(2):363-70. Unique Identifier : AIDSLINE MED/86035426
Jordan SC; Gautier E; Sakai R; Bahn L

Abstract: Two micro enzyme immunoassays (microEIA) for circulating immune complexes (CICs) are described. The Raji cell microEIA was similar in sensitivity, reproducibility and specificity to the Raji radioimmunoassay. The F(ab')2 anti-C3 microEIA was comparable to the 2 Raji cell assays. The 2 microEIAs for CICs were used to analyze sera from patients with systemic lupus erythematosus (SLE), the acquired immune deficiency syndrome (AIDS) and from hemophiliacs with AIDS-like symptoms. The microEIAs were very sensitive in detecting CICs in pathologic sera. In contrast, only 3% of normals (n = 30) were positive in the Raji microEIA while none were positive in the F(ab')2 anti-C3 microEIA. The initial high positivity of some normals (9/30) in the F(ab')2 microEIA was due to bovine serum albumin (BSA)-anti-BSA immune complex formation in vitro and was corrected when human albumin was used in buffer preparation instead of BSA. The reagents required for the microEIAs are more stable and less expensive than those required for the RIAs and the need for facilities to deal with 125-labeling and disposal is avoided.

Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY Antigen-Antibody Complex/*ANALYSIS Cell Line Complement 3/IMMUNOLOGY Hemophilia/IMMUNOLOGY Horseradish Peroxidase/DIAGNOSTIC USE Human *Immunoenzyme Techniques Immunoglobulins, Fab/IMMUNOLOGY Lupus Erythematosus, Systemic/IMMUNOLOGY Solubility Staphylococcal Protein A/DIAGNOSTIC USE Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. JOURNAL ARTICLE

860228
M8620129

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1986. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1986. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .